Open AccessPhase I study of sorafenib in patients with refractory or relapsed acute leukemias
Author(s) -
Gautam Borthakur,
Hagop M. Kantarjian,
Farhad Ravandi,
Weiguo Zhang,
Marina Konopleva,
John J. Wright,
Stefan Faderl,
Srđan Verstovšek,
Sheela Mathews,
Michael Andreeff,
Jorge Cortes
Publication year - 2010
Publication title -
haematologica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.782
H-Index - 142
eISSN - 1592-8721
pISSN - 0390-6078
DOI - 10.3324/haematol.2010.030452
Subject(s) - medicine , sorafenib , tyrosine kinase , oncology , leukemia , tyrosine kinase inhibitor , gastroenterology , cancer , hepatocellular carcinoma , receptor
Background Sorafenib is a multi-kinase inhibitor with activity against fms-like tyrosine kinase 3 with internal tandem duplication mutation and Raf kinase among others. A phase I dose escalation study of sorafenib was conducted in patients with advanced myelodysplastic syndrome and relapsed or refractory acute leukemias.